Fulcrum Therapeutics Inc. has released a corporate presentation detailing its strategic focus on developing oral small molecules aimed at modifying gene expression in rare diseases, particularly in the field of benign hematology. The presentation highlights Pociredir, a potential best-in-class oral small molecule for inducing fetal hemoglobin (HbF) in sickle cell disease $(SCD)$, which has received Fast Track and Orphan Drug Designations. Data disclosure for Phase 1b PIONEER trial cohorts is planned for early Q3 2025 and year-end 2025. Additionally, the company plans to submit an Investigational New Drug $(IND.AU)$ application in Q4 2025 and reports a cash position of $226.6 million as of March 31, 2025, providing a financial runway into at least 2027. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。